Combating Counterfeit Pharmaceuticals Act of 2025

This bill defines "copy-cat ingredients" as substances mimicking approved drugs but made via different processes or with lower quality, and clarifies "counterfeit drugs" under existing law. It updates the Fentanyl Sanctions Act to replace all references to "opioid" with "illicit drug," expanding the law's scope to cover all counterfeit pharmaceuticals - not just opioid-related products. The bill also adds a waiver allowing access to medications on the HHS drug shortage list. These changes help regulators and law enforcement better identify and address counterfeit drugs affecting patients and the healthcare system.